Related Experiment Videos
Metachromatic leukodystrophy: molecular genetics and an animal model
V Gieselmann1, U Matzner, B Hess
1Biochemisches Institut der Christian-Albrechts-Universität zu Kiel, Germany.
Journal of Inherited Metabolic Disease
|September 5, 1998
Summary
Metachromatic leukodystrophy (MLD) is a fatal genetic disorder. Arylsulphatase A (ASA)-deficient mice mimic MLD but show a mild phenotype; bone marrow gene therapy did not reduce storage material.
Area of Science:
- Biochemistry
- Genetics
- Neuroscience
Background:
- Metachromatic leukodystrophy (MLD) is a fatal lysosomal storage disorder caused by arylsulphatase A (ASA) deficiency.
- This deficiency leads to cerebroside sulphate accumulation, primarily affecting myelin and oligodendrocytes, resulting in progressive demyelination and neurological symptoms.
Purpose of the Study:
- To generate and characterize an animal model for MLD.
- To investigate the potential of bone marrow gene therapy for MLD.
Main Methods:
- Homologous recombination was used to create ASA knockout mice.
- Lipid storage, neurological abnormalities, and demyelination were assessed.
- Bone marrow transplantation with retrovirally transduced ASA was performed.
Main Results:
- ASA-deficient mice exhibit intralysosomal lipid storage, astrogliosis, decreased axonal diameter, and demyelination in specific tissues.
- The mice display deafness and neuromotor deficits but have a milder phenotype than human patients.
- Gene therapy via bone marrow transplantation led to sustained ASA expression but did not reduce storage material.
Conclusions:
- ASA-deficient mice serve as a valuable model for studying MLD pathogenesis.
- Current bone marrow gene therapy approaches show limited efficacy in reducing storage material in this model.